Sailong Pharmaceutical Group announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the Approval Notice for the Market Application of Active Pharmaceutical Ingredient Omeprazole Sodium issued by the National Medical Products Administration. The main indications of this active pharmaceutical ingredient are duodenal ulcers, gastric ulcers, reflux esophagitis, and Zollinger-Ellison syndrome.
赛隆药业：子公司获奥美拉唑钠原料药上市批准
Sailong Pharmaceutical Group: Subsidiary obtains approval for the market launch of omeprazole sodium active pharmaceutical ingredient.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.